FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912089449> ?p ?o ?g. }

• W2912089449 abstract "Introduction: Osteosarcoma is the most common pediatric high-grade bone tumor. Although multimodal therapeutic approaches have significantly improved patient survival to more than 60%, the prognosis for patients with metastatic or relapsed disease remains dismal—an urgent unmet need. Its genomic complexity and higher mutational burden compared to other pediatric cancers should provide neoantigens as potential targets for T cell-based immunotherapy; however, these tumors are in general “cold,” with insufficient or inactive tumor-infiltrating lymphocytes. Ganglioside GD2 is a tumor-associated surface antigen expressed in a broad spectrum of pediatric malignancies, including neuroblastoma, brain tumors, Ewing’s sarcoma, rhabdomyosarcoma, and osteosarcoma, while being restricted in normal tissues. Another promising target, HER2 or ErbB2, is overexpressed in many aggressive malignancies, including pediatric medulloblastoma, nephroblastoma, osteosarcoma, and desmoplastic small round cell tumor (DSRT). Fully humanized tetravalent bispecific antibodies (BsAb) specific for human GD2 and CD3 (hu3F8-BsAb) or HER2 and CD3 (HER2-BsAb), built on an IgG(L)-scFv platform, have been developed (Oncoimmunology 2017; Can Immunol Res 2015). They induce rapid and quantitative T-cell homing to tumors, mediating potent T-cell dependent cytotoxicity (TDCC) against GD2 or HER2 expressing tumor cells, effecting cures of xenografts in SCID mice. In this study, we evaluated the in vitro and in vivo antitumor properties of these BsAbs in the treatment of osteosarcoma. Methods: Hu3F8-BsAb and HER2-BsAb were tested both in vitro and in vivo against a panel of osteosarcoma cell lines (RG143B, U2OS, CRL1427, HOS, and SaOS2). Using these cell lines, FACS analysis for surface antigen (GD2 and HER2) expression (MFI), sensitivity to TDCC (EC50), and antitumor activity in vivo were evaluated. Two in vivo tumor models with different effector routes were used to simulate different clinical situations: 1) subcutaneous (sc) tumor cells/sc effector peripheral blood mononuclear cells (PBMCs), and 2) sc tumor cells/intravenous (iv) PBMCs. In vivo tumor responses were measured by Peira TM900 imaging device or by bioluminescence. Results: The majority of osteosarcoma cell lines express GD2 and HER2 on their surface, and their in vitro sensitivity to TDCC (EC50) was inversely correlated with MFI of their respective antigen. Both hu3F8-BsAb and HER2-BsAb mediated potent TDCC against osteosarcoma cell lines. In vivo, both hu3F8-BsAb and HER2-BsAb exerted a significant antitumor effect compared to control BsAb (P=0.001). Conclusions: Hu3F8-BsAb and HER2-BsAb induced strong TDCC and had significant antitumor effect against osteosarcoma cell lines both in vitro and in vivo. Considering the limited therapeutic options currently available in advanced osteosarcomas, these results support their further clinical development as potential T cell-based immunotherapeutics. Citation Format: Jeong A. Park, Hong Xu, Irene Cheung, Nai-Kong V. Cheung. Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr B38." @default.
• W2912089449 created "2019-02-21" @default.
• W2912089449 creator A5014211951 @default.
• W2912089449 creator A5034081882 @default.
• W2912089449 creator A5079175227 @default.
• W2912089449 creator A5083817841 @default.
• W2912089449 date "2018-10-01" @default.
• W2912089449 modified "2023-09-27" @default.
• W2912089449 title "Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy" @default.
• W2912089449 doi "https://doi.org/10.1158/1538-7445.pedca17-b38" @default.
• W2912089449 hasPublicationYear "2018" @default.
• W2912089449 type Work @default.
• W2912089449 sameAs 2912089449 @default.
• W2912089449 citedByCount "0" @default.
• W2912089449 crossrefType "proceedings-article" @default.
• W2912089449 hasAuthorship W2912089449A5014211951 @default.
• W2912089449 hasAuthorship W2912089449A5034081882 @default.
• W2912089449 hasAuthorship W2912089449A5079175227 @default.
• W2912089449 hasAuthorship W2912089449A5083817841 @default.
• W2912089449 hasConcept C121608353 @default.
• W2912089449 hasConcept C126322002 @default.
• W2912089449 hasConcept C142724271 @default.
• W2912089449 hasConcept C147483822 @default.
• W2912089449 hasConcept C150903083 @default.
• W2912089449 hasConcept C159654299 @default.
• W2912089449 hasConcept C203014093 @default.
• W2912089449 hasConcept C207001950 @default.
• W2912089449 hasConcept C2776715637 @default.
• W2912089449 hasConcept C2777701055 @default.
• W2912089449 hasConcept C2777760704 @default.
• W2912089449 hasConcept C2778256501 @default.
• W2912089449 hasConcept C2780844630 @default.
• W2912089449 hasConcept C502942594 @default.
• W2912089449 hasConcept C54355233 @default.
• W2912089449 hasConcept C71924100 @default.
• W2912089449 hasConcept C81885089 @default.
• W2912089449 hasConcept C86803240 @default.
• W2912089449 hasConceptScore W2912089449C121608353 @default.
• W2912089449 hasConceptScore W2912089449C126322002 @default.
• W2912089449 hasConceptScore W2912089449C142724271 @default.
• W2912089449 hasConceptScore W2912089449C147483822 @default.
• W2912089449 hasConceptScore W2912089449C150903083 @default.
• W2912089449 hasConceptScore W2912089449C159654299 @default.
• W2912089449 hasConceptScore W2912089449C203014093 @default.
• W2912089449 hasConceptScore W2912089449C207001950 @default.
• W2912089449 hasConceptScore W2912089449C2776715637 @default.
• W2912089449 hasConceptScore W2912089449C2777701055 @default.
• W2912089449 hasConceptScore W2912089449C2777760704 @default.
• W2912089449 hasConceptScore W2912089449C2778256501 @default.
• W2912089449 hasConceptScore W2912089449C2780844630 @default.
• W2912089449 hasConceptScore W2912089449C502942594 @default.
• W2912089449 hasConceptScore W2912089449C54355233 @default.
• W2912089449 hasConceptScore W2912089449C71924100 @default.
• W2912089449 hasConceptScore W2912089449C81885089 @default.
• W2912089449 hasConceptScore W2912089449C86803240 @default.
• W2912089449 hasLocation W29120894491 @default.
• W2912089449 hasOpenAccess W2912089449 @default.
• W2912089449 hasPrimaryLocation W29120894491 @default.
• W2912089449 hasRelatedWork W1571073982 @default.
• W2912089449 hasRelatedWork W1918281504 @default.
• W2912089449 hasRelatedWork W1982602011 @default.
• W2912089449 hasRelatedWork W2001379878 @default.
• W2912089449 hasRelatedWork W2069622785 @default.
• W2912089449 hasRelatedWork W2088209177 @default.
• W2912089449 hasRelatedWork W2132781781 @default.
• W2912089449 hasRelatedWork W2257891551 @default.
• W2912089449 hasRelatedWork W2410248950 @default.
• W2912089449 hasRelatedWork W2590902777 @default.
• W2912089449 isParatext "false" @default.
• W2912089449 isRetracted "false" @default.
• W2912089449 magId "2912089449" @default.
• W2912089449 workType "article" @default.